BioMarin (BMRN) PT Raised to $120 at Piper Jaffray
- Wall Street ends higher, investors juggle Fed nerves with AI enthusiasm
- Apple in talks with Google to use generative AI in iPhones- Bloomberg
- World shares cheer China data, as central banks line up
- Oil prices climb 2% to 4-month high on lower Iraq, Saudi exports
- Meta Platforms is a new Top Pick at Mizuho, analyst sees upside to consensus
- After-hours movers: ANSYS, National CineMedia, and more
- Midday movers: Google, Pepsi rise; Boeing, Zillow fall
- Midday movers: Adobe, Zillow fall; Micron rises
- After-hours movers: Adobe Systems slumps; Rivian, Ulta Beauty gain
- Midday movers: Tesla, Nvidia fall premarket; Robinhood, Dollar General rise
BioMarin Announces Second Quarter 2016 Financial Results
August 4, 2016 4:03 PM EDT- Second Quarter 2016 Total BioMarin Revenue Increases 20.0% Y/Y to $300.1 million
- Vimizim Net Product Revenue Increases 98.1% Y/Y and Contributes $106.8 million in the Second Quarter 2016; Vimizim Full-year Revenue Guidance Increased to $340 to $360 million
- Kuvan Net Product Revenue Contributes $90.2 million in the Second Quarter 2016; Kuvan Full-year Revenue Guidance Increased to $340 to $360 million
- Strong Kuvan and Vimizim Results Drive Increased FY 2016 Top-line Guidance to $1.10 billion - $1.15 billion
Financial Highlights (in millions of U.S. dollars, except per share data,... More